Alexander Kohlmann

16.2k citations

184 papers · 7.9k · 3 hit papers · h-index 45

Impact in

Hematology top 0.1%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 0.5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 123
- Acute Myeloid Leukemia Research 113
- Chronic Myeloid Leukemia Treatments 27
Molecular Biology 69
- Gene expression and cancer classification 21
- Advanced biosensing and bioanalysis techniques 14

Co-authors: Torsten Haferlach (147 shared papers)Susanne Schnittger (126 shared papers)Wolfgang Kern (118 shared papers)Claudia Haferlach (88 shared papers)Martin Dugas (35 shared papers)Claudia Schoch (32 shared papers)Vera Grossmann (30 shared papers)Frank Dicker (32 shared papers)
Journals: Blood (85 papers)Leukemia (13 papers)Genes Chromosomes and Cancer (10 papers)Annals of Oncology (5 papers)PLoS ONE (5 papers)
Partner nations: Germany United States United Kingdom

In The Last Decade

Alexander Kohlmann

180 papers receiving 7.7k citations

Alexander Kohlmann's Hit Papers

align trajectories log scale

Olaparib for Metastatic Castration-Resistant Prostate Cancer 2020 · 1.5k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 New England Journal of Medicine
2017 JAMA
2010 Journal of Clinical Oncology

Peers

Countries citing papers authored by Alexander Kohlmann

Since Specialization

Citations

This map shows the geographic impact of Alexander Kohlmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Kohlmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Kohlmann more than expected).

Fields of papers citing papers by Alexander Kohlmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Kohlmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Kohlmann. The network helps show where Alexander Kohlmann may publish in the future.

Co-authors

The 25 scholars most cited alongside Alexander Kohlmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alexander Kohlmann Line = papers co-authored together Alexander Kohlmann links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 184 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Olaparib for Metastatic Castration-Resistant Prostate Cancer New England Journal of Medicine ·Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph E. Burgents, Wenting Wu, Alexander Kohlmann, Carrie A. Adelman, Maha Hussain Hit paper breakdown →	2020	1473
2	Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group Journal of Clinical Oncology ·Torsten Haferlach, Alexander Kohlmann, Lothar Wieczorek, Giuseppe Basso, Geertruy te Kronnie, Marie C. Béné, John De Vos, Jesús María Hernández‐Rivas, Wolf-Karsten Hofmann, Ken Mills, Amanda Gilkes, Sabina Chiaretti, Sheila Shurtleff, Thomas J. Kipps, Laura Z. Rassenti, Allen Eng Juh Yeoh, Peter Papenhausen, Wei‐Min Liu, Paul Williams, Robin Foà Hit paper breakdown →	2010	494
3	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer JAMA ·Pasi A. Jänne, Michel M. van den Heuvel, Fabrice Barlési, Manuel Cobo, Julien Mazières, Lucio Crinò, С. В. Орлов, Fiona Blackhall, Juergen Wolf, Pilar Garrido, Artem Poltoratskiy, G Mariani, Dana Ghiorghiu, Elaine Kilgour, Paul D. Smith, Alexander Kohlmann, David Carlile, David Lawrence, Karin Bowen, Johan Vansteenkiste Hit paper breakdown →	2017	254
4	SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML) Blood ·Manja Meggendorfer, Andreas Roller, Torsten Haferlach, Christiane Eder, Frank Dicker, Vera Grossmann, Alexander Kohlmann, Tamara Alpermann, Kenichi Yoshida, Seishi Ogawa, H. Phillip Koeffler, Wolfgang Kern, Claudia Haferlach, Susanne Schnittger	2012	228
5	Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1 Journal of Clinical Oncology ·Alexander Kohlmann, Vera Großmann, Hans‐Ulrich Klein, Sonja Schindela, Tamara Weiss, Beray Kazak, Frank Dicker, Susanne Schnittger, Martin Dugas, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach	2010	226
6	Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles Proceedings of the National Academy of Sciences ·Claudia Schoch, Alexander Kohlmann, Susanne Schnittger, Benedikt Brors, Martin Dugas, Susanne Mergenthaler, Wolfgang Kern, Wolfgang Hiddemann, Roland Eils, Torsten Haferlach	2002	210
7	Landscape of TET2 mutations in acute myeloid leukemia Leukemia ·Sandra Weißmann, Tamara Alpermann, Vera Grossmann, Andreas Kowarsch, Niroshan Nadarajah, Christiane Eder, Frank Dicker, Annette Fasan, Claudia Haferlach, Torsten Haferlach, Wolfgang Kern, Susanne Schnittger, Alexander Kohlmann	2011	195
8	A novel hierarchical prognostic model of AML solely based on molecular mutations Blood ·Vera Grossmann, Susanne Schnittger, Alexander Kohlmann, Christiane Eder, Andreas Roller, Frank Dicker, Christoph Schmid, Clemens‐Martin Wendtner, Peter Staib, Hubert Serve, Karl‐Anton Kreuzer, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach	2012	185
9	Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome Nature Communications ·Vikas Madan, Deepika Kanojia, Jia Li, Ryoko Okamoto, Aiko Sato‐Otsubo, Alexander Kohlmann, Masashi Sanada, Vera Großmann, Janani Sundaresan, Yuichi Shiraishi, Satoru Miyano, Felicitas Thol, Arnold Ganser, Henry Yang, Torsten Haferlach, Seishi Ogawa, H. Phillip Koeffler	2015	176
10	ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome Leukemia ·Susanne Schnittger, Christiane Eder, Sabine Jeromin, Tamara Alpermann, Annette Fasan, Vera Grossmann, Alexander Kohlmann, Thomas Illig, N. Klopp, H-E Wichmann, K.-A. Kreuzer, Christoph Schmid, Peter Staib, Rudolf Peceny, Norbert Schmitz, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach	2012	161
11	Global approach to the diagnosis of leukemia using gene expression profiling Blood ·Torsten Haferlach, Alexander Kohlmann, Susanne Schnittger, Martin Dugas, Wolfgang Hiddemann, Wolfgang Kern, Claudia Schoch	2005	153
12	SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients Leukemia ·Sabine Jeromin, Sandra Weißmann, Claudia Haferlach, Frank Dicker, Katharina Bayer, Vera Grossmann, Tamara Alpermann, Andreas Roller, Alexander Kohlmann, Torsten Haferlach, Wolfgang Kern, Susanne Schnittger	2013	149
13	Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile Genes Chromosomes and Cancer ·Claudia Schoch, Wolfgang Kern, Alexander Kohlmann, Wolfgang Hiddemann, Susanne Schnittger, Torsten Haferlach	2005	139
14	The role of different genetic subtypes of CEBPA mutated AML Leukemia ·Annette Fasan, Claudia Haferlach, Tamara Alpermann, Sabine Jeromin, Vera Grossmann, Christiane Eder, Sandra Weißmann, Frank Dicker, Alexander Kohlmann, Sonja Schindela, Wolfgang Kern, Torsten Haferlach, Susanne Schnittger	2013	130
15	AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features Blood ·Claudia Haferlach, Cristina Mecucci, Susanne Schnittger, Alexander Kohlmann, Marco Mancini, Antonio Cuneo, Nicoletta Testoni, Giovanna Rege‐Cambrin, Antonella Santucci, Marco Vignetti, Paola Fazi, Maria Paola Martelli, Torsten Haferlach, Brunangelo Falini	2009	129
16	Identification of Differentially Expressed Genes in Scrapie-Infected Mouse Brains by Using Global Gene Expression Technology Journal of Virology ·Wei Xiang, Otto Windl, Gerda Wünsch, Martin Dugas, Alexander Kohlmann, Nicola Dierkes, Ingo M. Westner, Hans A. Kretzschmar	2004	127
17	Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC) PLoS ONE ·James Sherwood, Claire Corcoran, Helen Brown, Alan Sharpe, Milena Musilová, Alexander Kohlmann	2016	124
18	Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome Blood ·Ken Mills, Alexander Kohlmann, Paul Williams, Lothar Wieczorek, Wei‐Min Liu, Rachel Li, Wen Wei, David Bowen, H. Loeffler, Jesús María Hernández‐Rivas, Wolf‐Karsten Hofmann, Torsten Haferlach	2009	120
19	The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL Genes Chromosomes and Cancer ·Vera Grossmann, Claudia Haferlach, Sandra Weißmann, Andreas Roller, Sonja Schindela, Franziska Poetzinger, Kathrin Stadler, Frauke Bellos, Wolfgang Kern, Torsten Haferlach, Susanne Schnittger, Alexander Kohlmann	2013	120
20	TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis Blood ·Anna Stengel, Susanne Schnittger, Sandra Weißmann, Sabrina Kuznia, Wolfgang Kern, Alexander Kohlmann, Torsten Haferlach, Claudia Haferlach	2014	117

About Alexander Kohlmann

Alexander Kohlmann is a scholar working on Hematology, Molecular Biology, Genetics, Cancer Research and Public Health, Environmental and Occupational Health, having authored 184 papers that have together received 7.9k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (113 papers), Cancer Genomics and Diagnostics (32 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (31 papers), Chronic Myeloid Leukemia Treatments (27 papers), Chronic Lymphocytic Leukemia Research (25 papers), Acute Lymphoblastic Leukemia research (22 papers), Gene expression and cancer classification (21 papers) and Advanced biosensing and bioanalysis techniques (14 papers). The work is most often cited by research in Hematology (3.7k citations), Genetics (1.6k citations), Cancer Research (1.2k citations), Oncology (1.4k citations) and Molecular Biology (3.4k citations). Alexander Kohlmann has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Torsten Haferlach, Susanne Schnittger, Wolfgang Kern, Claudia Haferlach, Martin Dugas, Claudia Schoch, Vera Grossmann, Frank Dicker, Tamara Alpermann and Wolfgang Hiddemann. Their work appears in journals such as Blood, Leukemia, Genes Chromosomes and Cancer, Annals of Oncology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Alexander Kohlmann

Impact in

Papers in i

In The Last Decade

Alexander Kohlmann

Alexander Kohlmann's Hit Papers

Peers

Countries citing papers authored by Alexander Kohlmann

Fields of papers citing papers by Alexander Kohlmann

All Works

About Alexander Kohlmann

Explore authors with similar magnitude of impact

Papers in